Venomics AI: a computational exploration of global venoms for antibiotic discovery

Changge Guan [1-4, †], Marcelo D. T. Torres [1-4, †], Sufen Li[1-4], and Cesar de la Fuente-Nunez [1-4, *]

Affiliations:

[1]Machine Biology Group, Departments of Psychiatry and Microbiology, Institute for Biomedical Informatics, Institute for Translational Medicine and Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America.

[2]Departments of Bioengineering and Chemical and Biomolecular Engineering, School of Engineering and Applied Science, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America.

[3]Department of Chemistry, School of Arts and Sciences, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America.

[4]Penn Institute for Computational Science, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America.

[†]These authors contributed equally.

***Lead Contact:** Cesar de la Fuente-Nunez (cfuente@upenn.edu).

Abstract

The relentless emergence of antibiotic-resistant pathogens, particularly Gram-negative bacteria, highlights the urgent need for novel therapeutic interventions. Drug-resistant infections account for approximately 5 million deaths annually, yet the antibiotic development pipeline has largely stagnated. Venoms, representing a remarkably diverse reservoir of bioactive molecules, remain an underexploited source of potential antimicrobials. Venom-derived peptides, in particular, hold promise for antibiotic discovery due to their evolutionary diversity and unique pharmacological profiles. In this study, we mined comprehensive global venomics datasets to identify new antimicrobial candidates. Using machine learning, we explored 16,123 venom proteins, generating 40,626,260 venom-encrypted peptides (VEPs). Using APEX, a deep learning model combining a peptide-sequence encoder with neural networks for antimicrobial activity prediction, we identified 386 VEPs structurally and functionally distinct from known antimicrobial peptides. Our analyses showed that these VEPs possess high net charge and elevated hydrophobicity, characteristics conducive to bacterial membrane disruption. Structural studies revealed considerable conformational flexibility, with many VEPs transitioning to α-helical conformations in membrane-mimicking environments, indicative of their antimicrobial potential. Of the 58 VEPs selected for experimental validation, 53 displayed potent antimicrobial activity. Mechanistic assays indicated that VEPs primarily exert their effects through bacterial membrane depolarization, mirroring AMP-like mechanisms. *In vivo* studies using a mouse model of *Acinetobacter baumannii* infection demonstrated that lead VEPs significantly reduced bacterial burdens without notable toxicity. This study highlights the value of venoms as a resource for new antibiotics. By integrating computational approaches and experimental validation, venom-derived peptides emerge as promising candidates to combat the global challenge of antibiotic resistance.

Keywords: Deep learning, encrypted peptides, venoms, antibiotics, venom proteomes, proteome mining, peptides, machine learning.

Introduction

Drug-resistant infections account for approximately 5 million deaths annually worldwide[1], fueled by the rapid emergence of antibiotic-resistant pathogens. Among these, Gram-negative bacteria, identified as priority pathogens by the World Health Organization (WHO), are particularly adept at developing resistance. Despite this growing threat, the development pipeline for novel antibiotics has stagnated over the past few decades due to high costs and lengthy timelines, emphasizing the urgent need for innovative therapeutic strategies [2,3].

Animal venoms represent a promising source of new antibiotics[4–7]. These venoms are rich in bioactive peptides and proteins that exhibit diverse pharmacological effects, including antibacterial activity. Venom-derived peptides can target ion channels, cell membranes, and enzymes. For example, the cone snail toxin MVIIA (Ziconotide), marketed as Prialt®, is used to treat chronic pain by selectively targeting voltage-gated calcium channels[8].

Evolutionary studies have shown that venom genes originated from a small number of ancestral genes and diversified rapidly, resulting in a vast reservoir of chemical diversity[5].

Recent advances in bioinformatics and machine learning have enabled the systematic mining of potential antibiotic candidates from proteomes[9–16]. Using APEX, our sequence-to-function predictor[9,17], here we systematically identified potential antibiotics within venom proteomes and experimentally validated their antimicrobial activity. Notably, we identified venom protein-derived encrypted peptides (VEPs) with antimicrobial efficacy both *in vitro* and in preclinical animal models (**Figure 1a).** These findings highlight the immense, untapped potential of venomics to address the global challenge of antibiotic resistance.

Results

Mining venoms for new antibiotics

We sourced venom proteins from four databases: ConoServer (focusing on conopeptides, **Supplementary Figure 1**),[18] ArachnoServer (spider proteins, **Supplementary Figure 2**), [20] ISOB (indigenous snake proteins, **Supplementary Figure 3**),[22] and VenomZone (covering six taxa: snakes, scorpions, spiders, cone snails, sea anemones, and insects, **Supplementary Figure 4**)[24]. The VenomZone dataset,

95   curated from UniProtKB, was represented in our study by UniProt. Altogether, we

96   compiled 16,123 venom proteins, which were computationally processed to generate

97   40,626,260 VEPs.

98   To analyze differences across the four databases, we performed a species overlap

99   analysis (**Figure 1b**). UniProt contained the largest number of unique species (699),

100   reflecting its extensive coverage. Conoserver and Arachnoserver encompassed smaller

101   unique subsets (16 and 12, respectively), while ISOB contained no unique species.

102   These results highlight the complementary nature of these databases, emphasizing the

103   value of integrating multiple sources to achieve comprehensive venom protein diversity.

104   Using APEX, a deep learning model, we predicted bacterial strain-specific MIC values

105   for each peptide and used the mean MIC as a measure of antimicrobial activity. We

106   identified 7,379 VEPs with a mean MIC ≤ 32 µmol L^{-1} (**Data S1**). Further filtering

107   criteria (see **Methods**: "**Venom encrypted peptide selection**") based on sequence

108   similarity to known antimicrobial peptides (AMPs) yielded 386 candidates with low

109   similarity to existing AMPs (**Supplementary Table 1** and **Data S2**).

110   To visualize sequence diversity, we compared the 386 VEPs with 19,762 known AMPs

111   from the DBAASP database. Pairwise alignment (see **Methods**: **"Peptide sequence**

112   **similarity"**) and uniform manifold approximation and projection (UMAP) revealed that

113   most known AMPs clustered densely, reflecting high sequence similarity matrix

114   (**Figure 1c**).

115   Most known AMPs formed a dense cluster, indicating high sequence similarity, with a

116   minority scattered outside this cluster, representing more diverse sequences. VEPs

117   derived from ConoServer and ArachnoServer tended to cluster closer to known AMPs,

118   reflecting relatively higher sequence similarity. In contrast, UniProt-derived VEPs

119   mapped farther from the AMP cluster, partially overlapping with scattered AMPs and

120   occupying previously unexplored regions of sequence space. ISOB-derived VEPs were

121   the most distant from known AMPs, forming isolated clusters that represent a promising

122   source of completely novel AMP sequences (**Figure 1c**).

123   To determine whether VEPs with low sequence similarity to known AMPs share key

124   physicochemical characteristics, we analyzed their distribution in physicochemical

125   feature space (**Supplementary Figure 5**). While known AMPs from DBAASP

126   clustered centrally, UniProt-derived VEPs formed three distinct clusters,

127   Arachnoserver-derived VEPs formed two clusters, and ISOB and Conoserver each

128   formed one cluster. UniProt cluster overlapped with ConoServer, while the ISOB-

129   derived cluster remained entirely isolated. UniProt- and Arachnoserver-derived clusters

130   that did not overlap with known AMPs represent unexplored regions of sequence space

131   (**Figure 1c**).

132   These findings suggest that our approach identifies both AMP-like peptides that differ

133   in sequence while sharing similar physicochemical properties and entirely different

134   AMP families that deviate in both sequence and characteristics.

135   **Composition and physicochemical features**

136   A comparison of amino acid composition between VEPs and DBAASP AMPs revealed

137   distinct profiles (**Figure 1d** and **Supplementary Figure 6**). VEPs had lower cysteine,

138   aspartic acid, histidine, and isoleucine, while showing higher phenylalanine, lysine, and

139   arginine content. ISOB-derived VEPs were particularly enriched in phenylalanine,

140   whereas Conoserver-derived VEPs displayed pronounced arginine content. Notably,

141   Arachnoserver- and ISOB-derived VEPs were enriched in lysine.

142   To further understand the physicochemical properties contributing to antimicrobial

143   activity, we benchmarked VEPs against known AMPs (**Figure 1e-f, Supplementary**

144   **Figure 7**). VEPs were generally more positively charged, facilitating electrostatic

145   interactions with the negatively charged bacterial membranes[22]. They also exhibited

146   slightly higher normalized hydrophobicity, likely driven by their increased

147   phenylalanine and arginine content. In ISOB- and Conoserver-derived VEPs, these

148   features enhanced amphiphilicity (**Supplementary Figure 7a**), promoting secondary

149   structure formation and membrane-associated activity.

150   Additionally, VEPs displayed higher isoelectric points than known AMPs

151   (**Supplementary Figure 7b**), consistent with their elevated cationic residue content. By

152   design, the APEX model excluded peptides with high cysteine content, thereby avoiding

153   many Conoserver-derived peptides rich in disulfide bridges. Despite their elevated

154   phenylalanine levels, VEPs maintained comparable normalized hydrophobic moments

155   (**Supplementary Figure 7c**) and aggregation propensities (**Supplementary Figure 7d**)

156   to conventional AMPs, with amphiphilic distribution likely mitigating hydrophobic

157   clustering.

5

158   Collectively, these results delineate the unique composition and physicochemical
159   properties of VEPs, highlighting their potential as promising antimicrobial candidates.

160   **Antimicrobial Activity Assays**

161   Among the 58 VEPs tested, 53 (91.4%) exhibited activity against at least one
162   pathogenic strain. Notably, all Arachnoserver-derived peptides were active,
163   emphasizing their strong antimicrobial potential (**Figure 2a**). In contrast, some UniProt-
164   derived VEPs (from VenomZone) demonstrated limited potency: UniprotKB-2 showed
165   no activity, while UniprotKB-6 and UniprotKB-11 were active only against
166   *Enterococcus faecium*.

167   The inactive or minimal activity of UniProtKB-2, -6, and -11 was associated with lower
168   hydrophobicity and net charge, underscoring the important role of these parameters in
169   facilitating membrane interactions. Conversely, ISOB-derived VEPs with enhanced
170   normalized hydrophobicity exhibited improved antimicrobial performance. Among
171   Conoserver-derived VEPs, an intermediate balance of hydrophobicity and net charge
172   appeared to be optimal for activity. In Arachnoserver-derived VEPs, where all
173   candidates were active, efficacy seemed to be driven by sequence-specific features
174   rather than general physicochemical properties.

175   These findings underscore the importance of physicochemical characteristics, such as
176   charge and hydrophobicity, in effective bacterial membrane disruption while also
177   highlighting the significant role of sequence-specific factors in determining
178   antimicrobial efficacy.

179   **Secondary structure studies**

180   The secondary structure of short peptides is inherently dynamic, often transitioning
181   between disordered and ordered conformations depending on the surrounding
182   environment, particularly at hydrophobic/hydrophilic interfaces. These structural
183   transitions are critical for defining the biological functions of peptides, including their
184   antimicrobial activity.

185   To investigate the structural behavior of the synthesized VEPs, we performed Circular
186   Dichroism (CD) spectroscopy in diverse environments: water, sodium dodecyl sulfate
187   (SDS)/water (10 mmol L⁻¹), methanol (MeOH)/water (1:1, v:v), and trifluoroethanol
188   (TFE)/water (3:2, v:v). Each medium was chosen to simulate specific physicochemical
189   conditions relevant to peptide behavior. SDS micelles mimic biological lipid bilayers,

190   offering a membrane-like environment conducive to evaluating interactions with

191   bacterial membranes[19]. The TFE/water mixture is a known helical-inducer that

192   promotes intramolecular hydrogen bonding by dehydrating peptide backbone amide

193   groups, thereby favoring α-helical conformations[21,23]. Conversely, the MeOH/water

194   mixture promotes interchain hydrogen bonding, stabilizing β-like structures, while

195   hydrophobic side chains cluster to minimize contact with water, enhancing β-like

196   conformations[25].

197   CD spectra were recorded for all VEPs at 50 µmol L^{-1} over a wavelength range of 260

198   to 190 nm (**Supplementary Figure 8a-d**). The Beta Structure Selection (BeStSel)

199   algorithm was employed to deconvolute the spectra and quantify the secondary structure

200   content[26] (**Figure 2b-e**). As expected for short peptides (<50 amino acid residues),

201   VEPs were predominantly unstructured in water (**Figure 2b** and **Supplementary**

202   **Figure 8a,e**), though with a slight propensity toward β-like conformations ($f_\beta < 45\%$;

203   **Supplementary Figure 8e**). A similar trend was observed in the β-inducing medium

204   (MeOH/water), where the β-content modestly increased (**Figure 2e** and

205   **Supplementary Figure 8d-e**).

206   In contrast, VEPs exhibited a pronounced structural transition in SDS micelles (**Figure**

207   **2c** and **Supplementary Figure 8c,e**) and TFE/water mixture (3:2, v:v; **Figure 2d** and

208   **Supplementary Figure 8b,e**), adopting α-helical conformations. This shift from

209   disordered to α-helical structures highlights their responsiveness to membrane-

210   mimicking environments and helical-inducing media, consistent with typical behavior

211   observed for antimicrobial peptides[6,27,28].

212   Interestingly, this behavior distinguishes VEPs from other classes of encrypted peptides,

213   including those predicted by earlier proteome mining of APEX[9], which predominantly

214   adopted unstructured or β-like conformations, even in membrane-like or helical-

215   inducing environments. Similarly, small open reading frame-encoded peptides (SEPs)

216   and bacterial proteome-derived encrypted peptides[29,30] showed limited helical

217   propensity under comparable conditions. Instead, VEPs exhibited a structural response

218   more akin to archaeasins, which also demonstrated a clear transition to α-helical

219   conformations in helical-inducing media and upon interacting with lipid bilayers[17].

220   These findings suggest that VEPs may be uniquely suited for membrane-associated

221   functions, likely contributing to their observed antimicrobial efficacy.

7

Mechanism of action studies

To investigate whether VEPs exert their activity via membrane-related mechanisms, we evaluated their effects on bacterial outer and cytoplasmic membranes using fluorescence assays. We used 1-(N-phenylamino)-naphthalene (NPN) assays to assess bacterial outer membrane permeabilization (**Figure 3a**). Among the peptides tested, 23 VEPs effectively permeabilized the outer membrane. Notably, Arachnoserver-18, derived from the protein M-oxotoxin-Ot2d of the spider *Oxyopes takobius*; ConoServer-6, derived from the protein Bt211 precursor, a widely studied conotoxin from the betuline cone (*Conus betulinus*); and ConoServer-7, derived from the protein Con-ins G1b precursor of *Conus geographus*, a cone snail known for having the most potent venom among the *Conus* genus[31], showed superior permeabilization activity. Polymyxin B and levofloxacin were as controls in these experiments[11]. Overall, VEPs demonstrated permeabilization comparable to or better than other AMPs[7,32,33] or other human- or animal-derived EPs[9,11].

We next evaluated cytoplasmic membrane depolarization using $3,3'$-dipropylthiadicarbocyanine iodide (DiSC$_3$-5), a fluorophore that detects membrane potential changes. Among the 28 peptides tested against *P. aeruginosa* PAO1, 26 VEPs depolarized the cytoplasmic membrane more effectively than the control groups treated with polymyxin B and levofloxacin (**Figure 3b**)[11]. However, the depolarization efficacy of VEPs was less pronounced compared to other peptide families[29], such as those derived from the archaeal proteome (archaeasins)[17] and SEPs[29]. Against the Gram-positive bacterium *S. aureus*, VEPs exhibited slightly better depolarization activity than *P. aeruginosa* (**Figure 3c**), though their performance remained below that of other reported peptide depolarizers [10,30].

These findings suggest that VEPs primarily exert their antimicrobial effects through cytoplasmic membrane depolarization rather than outer membrane permeabilization. This mode of action aligns with that of conventional AMPs [32,33] and EPs[11] but differs from certain computationally predicted peptides[29].

***In vitro* cytotoxicity of VEPs**

Cytotoxicity was assessed using human embryonic kidney (HEK293T) cells. Some VEPs were cytotoxic at HC$_{50}$ ≤ 64 µmol L^{-1} (**Figure 4a**), mirroring their potent antimicrobial activity. These findings underscore the importance of fine-tuning VEP

254 properties to balance antimicrobial efficacy with reduced cytotoxicity, guiding further

255 peptide optimization.

Anti-infective activity in preclinical animal models

257 To determine the *in vivo* efficacy of lead VEPs, we used a skin abscess mouse model

258 infected with *A. baumannii*, a clinically significant pathogen (**Figure 4b**). Three VEPs

259 demonstrated promising activity: UniProtKB-7, derived from the Im-1 toxin of the

260 scorpion *Isometrus maculatus*; ConoServer-14, derived from the Elevenin-Vc1 protein

261 of the cone snail *Conus quercinus*; and Arachnoserver-5, derived from the M-lycotoxin-

262 Gri2c protein of the wolf spider *Geolycosa riograndae*.

263 A single topical dose of each VEP at its MIC significantly reduced bacterial counts two

264 days post-infection. Arachnoserver-5 achieved a two-log reduction in bacterial load,

265 comparable to the activity of polymyxin B and levofloxacin controls. Four days post-

266 infection, all three VEPs continued to suppress bacterial growth, with Arachnoserver-5

267 producing a three-log reduction relative to untreated controls (**Figure 4c**). Importantly,

268 no significant changes in body weight were observed in treated animals, indicating

269 minimal toxicity under these conditions (**Supplementary Figure 10**).

270

Discussion

272 This study highlights the potential of computational exploration of venom proteomes,

273 integrating machine learning-driven predictions with experimental validation, to

274 uncover novel antibiotic candidates. The VEPs identified in this work exhibit distinct

275 sequence and physicochemical properties, retain membrane-active mechanisms

276 characteristic of known antimicrobial peptides (AMPs), and demonstrate promising

277 antimicrobial activity in both *in vitro* assays and preclinical animal models.

278 Our findings highlight the power of combining digital data and machine learning to

279 accelerate antibiotic discovery. By tapping into the underexplored biodiversity of

280 venom-derived proteins, we have uncovered a promising new class of antimicrobial

281 agents.

282

Limitations of the study

284 While APEX has proven effective in accelerating the discovery of novel antimicrobials,
285 several limitations remain. One significant constraint is its reliance on discrete MIC
286 values, which are recorded in multiples of 2, and the exclusive use of AAindex features,
287 limiting prediction accuracy and generalizability. Additionally, the model restricts input
288 sequence length to 50 residues, favoring peptides that are easier to chemically
289 synthesize but compromising prediction accuracy for longer sequences. Another notable
290 limitation is the lack of interpretability in APEX's predictions, as it does not identify
291 specific sequence features responsible for AMP activity, thereby limiting mechanistic
292 insights.

293 To address these limitations and enhance APEX's utility, several strategies can be
294 implemented. Introducing self-attention mechanisms could improve model
295 interpretability by pinpointing critical sequence features that drive antimicrobial activity.
296 Expanding the training dataset to include longer sequences would improve prediction
297 accuracy for peptides exceeding the 50-residue threshold. Employing data augmentation
298 techniques could enhance generalizability across diverse peptide datasets. Additionally,
299 integrating large language models could capture complex sequence relationships, further
300 improving prediction accuracy and broadening APEX's applicability.

301

315   Molecules were rendered using the PyMOL Molecular Graphics System, Version 3.1.1

316   Schrödinger, LLC.

317

318   **Author contributions:**

319   Conceptualization: MDTT, CG, CFN

320   Methodology: MDTT, CG, CFN

321   Experimental investigation: MDTT, SL

322   Computational investigation: CG

323   Visualization: MDTT, CG

324   Funding acquisition: CFN

325   Supervision: CFN

326   Formal analysis: MDTT, CG

327   Writing – original draft: MDTT, CG, CFN

328   Writing – review & editing: MDTT, CG, CFN

329

330   **Competing interests:** Cesar de la Fuente-Nunez provides consulting services to Invaio

331   Sciences and is a member of the Scientific Advisory Boards of Nowture S.L. and Phare

332   Bio. The de la Fuente Lab has received research funding or in-kind donations from

333   United Therapeutics, Strata Manufacturing PJSC, and Procter & Gamble, none of which

334   were used in support of this work. An invention disclosure associated with this work has

335   been filed.

336

337   **Data availability**

338   The main data supporting the results in this study are available within the paper and

339   Data S1 and S2 files (DOI: 10.17632/9m4g52grhj.1). All data generated in this study,

340   including Source Data for the figures are available from the corresponding author on

341   reasonable request.

342
343   **Code availability**

344   APEX is available at GitLab: https://gitlab.com/machine-biology-group-public/apex.

345

346   **Figures:**

347

348   **Figure 1. Exploration of global venoms for antibiotic discovery. (a)** Mining
349   framework for AMPs. Our framework employs a three-stage approach to identify novel
350   AMP candidates from venom proteins. Initially, a peptide library is generated using a
351   sliding window method, extracting peptides ranging from 8 to 50 amino acid residues in
352   length. Subsequently, Minimum Inhibitory Concentration (MIC) values of a peptides
353   against bacterial strains were predicted by APEX. Finally, candidate VEPs are selected
354   based on sequence similarity, yielding a set of unique and potent molecules. **(b)** Venn
355   diagram illustrating species overlap among the four databases used as source of venom
356   proteins. Species names extracted from these databases were analyzed to identify

357   diversity. **(c)** Physicochemical feature space exploration. The graph illustrates a

358   bidimensional sequence space visualization of peptide sequences found in DBAASP

359   and antimicrobial venom-derived EPs (VEPs) discovered by APEX in venom proteins

360   from multiple source organisms. The physicochemical features were calculated for

361   peptide sequences which was made up of the feature vector for representing peptide.

362   Each row in the matrix represents a feature representation of a peptide based on its

363   amino acid composition. Uniform Manifold Approximation and Projection (UMAP)

364   was applied to reduce the feature representation to two dimensions for visualization. **(d)**

365   Comparison of amino acid frequency in VEPs with known antimicrobial peptides

366   (AMPs) from the DBAASP, APD3, and DRAMP 3.0 databases. Distribution of two

367   physicochemical properties for peptides with predicted antimicrobial activity, compared

368   with AMPs from DBAASP, APD3, and DRAMP 3.0: **(e)** net charge and **(f)** normalized

369   hydrophobicity. Net charge influences the initial electrostatic interactions between the

370   peptide and negatively charged bacterial membranes, while hydrophobicity affects

371   interactions with lipids in the membrane bilayers. Statistical significance in **e** and **f** was

372   determined using two-tailed t-tests followed by Mann–Whitney test; P values are shown

373   in the graph. The solid line inside each box represents the mean value for each group.

374

Figure 2. Antimicrobial activity and secondary structure profiles of antibiotics from venoms. (a) Heat map displaying the antimicrobial activities ($\mu mol \cdot L^{-1}$) of active antimicrobial agents from venoms against 11 clinically relevant pathogens, including antibiotic-resistant strains. Briefly, 10^5 bacterial cells were incubated with serially diluted VEPs (1–64 $\mu mol \cdot L^{-1}$) at 37 °C. Bacterial growth was assessed by measuring the optical density at 600 nm in a microplate reader one day post-treatment. The MIC values presented in the heat map represent the mode of the replicates for each condition. **(b)** Ternary plots showing the percentage of secondary structure for each peptide (at 50 $\mu mol\ L^{-1}$) in four different solvents: water, 60% trifluoroethanol (TFE) in water, 50% methanol (MeOH) in water, and Sodium dodecyl sulfate (SDS, 10 mmol L^{-1}) in water. Secondary structure fractions were calculated using the BeStSel server[26]. Circles indicate active VEPs, while crosses represent inactive peptides.

Figure 3. Mechanism of action of antibiotics from venoms. To assess whether VEPs act on bacterial membranes, all active peptides against *P. aeruginosa* PAO1 were subjected to outer membrane permeabilization and peptides active against *P. aeruginosa* PAO1 and *S. aureus* ATCC 12600 were tested in cytoplasmic membrane depolarization assays. The fluorescent probe 1-(N-phenylamino)naphthalene (NPN) was used to assess membrane permeabilization **(a)** induced by the tested VEPs. The fluorescent probe 3,3'-dipropylthiadicarbocyanine iodide (DiSC$_3$-5) was used to evaluate membrane depolarization **(b)** caused by VEPs. The values displayed represent the relative fluorescence of both probes, with non-linear fitting compared to the baseline of the untreated control (buffer + bacteria + fluorescent dye) and benchmarked against the antibiotics polymyxin B and levofloxacin. All experiments were performed in three independent replicates. The protein and peptide structures depicted in the figure were created with PyMOL Molecular Graphics System, version 3.1 Schrödinger, LLC.

Figure 4. Cytotoxic and anti-infective activity of antibiotics from venoms. (a) Heatmap exhibiting the cytotoxic concentrations leading to 50% cell lysis (CC□□) in human embryonic kidney (HEK293T) cells, determined by interpolating dose-response data using a nonlinear regression curve. All experiments were performed in three independent replicates. **(b)** Schematic representation of the skin abscess mouse model used to assess the anti-infective activity of VEPs (n□=□6) against *A. baumannii* ATCC 19606. **(b)** UniprotKB-7, conoserver-14, and arachnoserver-5 were administered at their MIC in a single dose two hours post-infection. Arachnoserver-5 inhibited the proliferation of the infection for up to 4□days after treatment compared to the untreated control group at levels comparable to the control antibiotics, polymyxin B and levofloxacin.

16

419

References

1. Murray, C.J.L., Ikuta, K.S., Sharara, F., Swetschinski, L., Robles Aguilar, G., Gray, A., Han, C., Bisignano, C., Rao, P., Wool, E., et al. (2022). Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. The Lancet *399*, 629–655. https://doi.org/10.1016/S0140-6736(21)02724-0.

2. Magana, M., Pushpanathan, M., Santos, A.L., Leanse, L., Fernandez, M., Ioannidis, A., Giulianotti, M.A., Apidianakis, Y., Bradfute, S., Ferguson, A.L., et al. (2020). The value of antimicrobial peptides in the age of resistance. Lancet Infect Dis. https://doi.org/10.1016/S1473-3099(20)30327-3.

3. de la Fuente-Nunez, C., Torres, M.D., Mojica, F.J., and Lu, T.K. (2017). Next-generation precision antimicrobials: towards personalized treatment of infectious diseases. Curr Opin Microbiol *37*, 95–102. https://doi.org/10.1016/j.mib.2017.05.014.

4. von Reumont, B.M., Anderluh, G., Antunes, A., Ayvazyan, N., Beis, D., Caliskan, F., Crnković, A., Damm, M., Dutertre, S., Ellgaard, L., et al. (2022). Modern venomics—Current insights, novel methods, and future perspectives in biological and applied animal venom research. Gigascience *11*. https://doi.org/10.1093/gigascience/giac048.

5. Kaas, Q., and Craik, D. (2015). Bioinformatics-Aided Venomics. Toxins (Basel) *7*, 2159–2187. https://doi.org/10.3390/toxins7062159.

6. Torres, M.D.T., Pedron, C.N., Higashikuni, Y., Kramer, R.M., Cardoso, M.H., Oshiro, K.G.N., Franco, O.L., Silva Junior, P.I., Silva, F.D., Oliveira Junior, V.X., et al. (2018). Structure-function-guided exploration of the antimicrobial peptide polybia-CP identifies activity determinants and generates synthetic therapeutic candidates. Commun Biol *1*, 221. https://doi.org/10.1038/s42003-018-0224-2.

7. Pedron, C.N., Torres, M.D.T., Oliveira, C.S., Silva, A.F., Andrade, G.P., Wang, Y., Pinhal, M.A.S., Cerchiaro, G., da Silva Junior, P.I., da Silva, F.D., et al. (2023). Molecular hybridization strategy for tuning bioactive peptide function. Commun Biol *6*, 1067. https://doi.org/10.1038/s42003-023-05254-7.

8. Miljanich, G.P. (2004). Ziconotide: Neuronal Calcium Channel Blocker for Treating Severe Chronic Pain. Curr Med Chem *11*, 3029–3040. https://doi.org/10.2174/0929867043363884.

9. Wan, F., Torres, M.D.T., Peng, J., and de la Fuente-Nunez, C. (2024). Deep-learning-enabled antibiotic discovery through molecular de-extinction. Nat Biomed Eng *8*, 854–871. https://doi.org/10.1038/s41551-024-01201-x.

10. Maasch, J.R.M.A., Torres, M.D.T., Melo, M.C.R., and de la Fuente-Nunez, C. (2023). Molecular de-extinction of ancient antimicrobial peptides enabled by machine learning. Cell Host Microbe *31*, 1260–1274. https://doi.org/10.1016/j.chom.2023.07.001.

17

460   11.   Torres, M.D.T., Melo, M.C.R., Flowers, L., Crescenzi, O., Notomista, E., and de
461   la Fuente-Nunez, C. (2022). Mining for encrypted peptide antibiotics in the
462   human proteome. Nat Biomed Eng *6*, 67–75. https://doi.org/10.1038/s41551-021-
463   00801-1.

464   12.   Porto, W.F., Irazazabal, L., Alves, E.S.F., Ribeiro, S.M., Matos, C.O., Pires,
465   Á.S., Fensterseifer, I.C.M., Miranda, V.J., Haney, E.F., Humblot, V., et al.
466   (2018). In silico optimization of a guava antimicrobial peptide enables
467   combinatorial exploration for peptide design. Nat Commun *9*, 1490.
468   https://doi.org/10.1038/s41467-018-03746-3.

469   13.   Liu, G., Catacutan, D.B., Rathod, K., Swanson, K., Jin, W., Mohammed, J.C.,
470   Chiappino-Pepe, A., Syed, S.A., Fragis, M., Rachwalski, K., et al. (2023). Deep
471   learning-guided discovery of an antibiotic targeting Acinetobacter baumannii.
472   Nat Chem Biol *19*, 1342–1350. https://doi.org/10.1038/s41589-023-01349-8.

473   14.   Wong, F., Zheng, E.J., Valeri, J.A., Donghia, N.M., Anahtar, M.N., Omori, S.,
474   Li, A., Cubillos-Ruiz, A., Krishnan, A., Jin, W., et al. (2024). Discovery of a
475   structural class of antibiotics with explainable deep learning. Nature *626*, 177–
476   185. https://doi.org/10.1038/s41586-023-06887-8.

477   15.   Stokes, J.M., Yang, K., Swanson, K., Jin, W., Cubillos-Ruiz, A., Donghia, N.M.,
478   MacNair, C.R., French, S., Carfrae, L.A., Bloom-Ackermann, Z., et al. (2020). A
479   Deep Learning Approach to Antibiotic Discovery. Cell *180*, 688-702.e13.
480   https://doi.org/10.1016/j.cell.2020.01.021.

481   16.   Torres, M.D.T., Cesaro, A., and de la Fuente-Nunez, C. (2024). Peptides from
482   non-immune proteins target infections through antimicrobial and
483   immunomodulatory properties. Trends Biotechnol.
484   https://doi.org/10.1016/j.tibtech.2024.09.008.

485   17.   Torres, M.D.T., Wan, F., and de la Fuente-Nunez, C. (2024). Discovery of
486   antibiotics in the archaeome using deep learning. bioRXiv.

487   18.   Kaas, Q., Yu, R., Jin, A.-H., Dutertre, S., and Craik, D.J. (2012). ConoServer:
488   updated content, knowledge, and discovery tools in the conopeptide database.
489   Nucleic Acids Res *40*, D325–D330. https://doi.org/10.1093/nar/gkr886.

490   19.   Renthal, R., Brancaleon, L., Peña, I., Silva, F., and Chen, L.Y. (2011). Interaction
491   of a two-transmembrane-helix peptide with lipid bilayers and dodecyl sulfate
492   micelles. Biophys Chem *159*, 321–327.
493   https://doi.org/10.1016/j.bpc.2011.08.005.

494   20.   Pineda, S.S., Chaumeil, P.-A., Kunert, A., Kaas, Q., Thang, M.W.C., Le, L.,
495   Nuhn, M., Herzig, V., Saez, N.J., Cristofori-Armstrong, B., et al. (2018).
496   ArachnoServer 3.0: an online resource for automated discovery, analysis and
497   annotation of spider toxins. Bioinformatics *34*, 1074–1076.
498   https://doi.org/10.1093/bioinformatics/btx661.

499   21.   Luo, P., and Baldwin, R.L. (1997). Mechanism of helix induction by
500   trifluoroethanol: A framework for extrapolating the helix-forming properties of

501   peptides from trifluoroethanol/water mixtures back to water. Biochemistry *36*,
502   8413–8421. https://doi.org/10.1021/bi9707133.

503   22.   Roly, Z.Y., Hakim, M.A., Zahan, A.S., Hossain, M.M., and Reza, M.A. (2015).
504   ISOB: A Database of Indigenous Snake Species of Bangladesh with respective
505   known venom composition. Bioinformation *11*, 107–114.
506   https://doi.org/10.6026/97320630011107.

507   23.   Fioroni, M., Burger, K., Mark, A.E., and Roccatano, D. (2000). A new 2,2,2-
508   trifluoroethanol model for molecular dynamics simulations. Journal of Physical
509   Chemistry B *104*, 12347–12354. https://doi.org/10.1021/jp002115v.

510   24.   The UniProt Consortium (2019). UniProt: a worldwide hub of protein
511   knowledge. Nucleic Acids Res *47*, D506–D515.
512   https://doi.org/10.1093/nar/gky1049.

513   25.   Hwang, S., Shao, Q., Williams, H., Hilty, C., and Gao, Y.Q. (2011). Methanol
514   Strengthens Hydrogen Bonds and Weakens Hydrophobic Interactions in Proteins
515   – A Combined Molecular Dynamics and NMR study. J Phys Chem B *115*, 6653–
516   6660. https://doi.org/10.1021/jp111448a.

517   26.   Micsonai, A., Moussong, É., Wien, F., Boros, E., Vadászi, H., Murvai, N., Lee,
518   Y.-H., Molnár, T., Réfrégiers, M., Goto, Y., et al. (2022). BeStSel: webserver for
519   secondary structure and fold prediction for protein CD spectroscopy. Nucleic
520   Acids Res *50*, W90–W98. https://doi.org/10.1093/nar/gkac345.

521   27.   Torres, M.D.T., Sothiselvam, S., Lu, T.K., and de la Fuente-Nunez, C. (2019).
522   Peptide Design Principles for Antimicrobial Applications. J Mol Biol *431*, 3547–
523   3567. https://doi.org/10.1016/j.jmb.2018.12.015.

524   28.   Zelezetsky, I., and Tossi, A. (2006). Alpha-helical antimicrobial peptides-Using a
525   sequence template to guide structure-activity relationship studies. Biochim
526   Biophys Acta Biomembr *1758*, 1436–1449.
527   https://doi.org/10.1016/j.bbamem.2006.03.021.

528   29.   Torres, M.D.T., Brooks, E.F., Cesaro, A., Sberro, H., Gill, M.O., Nicolaou, C.,
529   Bhatt, A.S., and de la Fuente-Nunez, C. (2024). Mining human microbiomes
530   reveals an untapped source of peptide antibiotics. Cell *187*, 5453–5467.
531   https://doi.org/10.1016/j.cell.2024.07.027.

532   30.   Santos-Júnior, C.D., Torres, M.D.T., Duan, Y., Rodríguez del Río, Á., Schmidt,
533   T.S.B., Chong, H., Fullam, A., Kuhn, M., Zhu, C., Houseman, A., et al. (2024).
534   Discovery of antimicrobial peptides in the global microbiome with machine
535   learning. Cell *187*, 3761–3778. https://doi.org/10.1016/j.cell.2024.05.013.

536   31.   Yoshiba, S. (1984). An estimation of the most dangerous species of cone shell
537   Conus (Gastridium) geographus Linne, 1758, venom's lethal dose in humans.
538   Nippon Eiseigaku Zasshi (Japanese Journal of Hygiene) *39*, 565–572.
539   https://doi.org/10.1265/jjh.39.565.

540   32.   Boaro, A., Ageitos, L., Torres, M.D.T., Blasco, E.B., Oztekin, S., and de la
541   Fuente-Nunez, C. (2023). Structure-function-guided design of synthetic peptides

542   with anti-infective activity derived from wasp venom. Cell Rep Phys Sci *4*,
543   101459. https://doi.org/10.1016/j.xcrp.2023.101459.

544   33.   Silva, O.N., Torres, M.D.T., Cao, J., Alves, E.S.F., Rodrigues, L. V., Resende,
545   J.M., Lião, L.M., Porto, W.F., Fensterseifer, I.C.M., Lu, T.K., et al. (2020).
546   Repurposing a peptide toxin from wasp venom into antiinfectives with dual
547   antimicrobial and immunomodulatory properties. Proceedings of the National
548   Academy of Sciences *117*, 26936–26945.
549   https://doi.org/10.1073/pnas.2012379117.

550   34.   Pirtskhalava, M., Amstrong, A.A., Grigolava, M., Chubinidze, M.,
551   Alimbarashvili, E., Vishnepolsky, B., Gabrielian, A., Rosenthal, A., Hurt, D.E.,
552   and Tartakovsky, M. (2021). DBAASP v3: database of antimicrobial/cytotoxic
553   activity and structure of peptides as a resource for development of new
554   therapeutics. Nucleic Acids Res *49*, D288–D297.
555   https://doi.org/10.1093/nar/gkaa991.

556   35.   Pirtskhalava, M., Amstrong, A.A., Grigolava, M., Chubinidze, M.,
557   Alimbarashvili, E., Vishnepolsky, B., Gabrielian, A., Rosenthal, A., Hurt, D.E.,
558   and Tartakovsky, M. (2021). DBAASP v3: database of antimicrobial/cytotoxic
559   activity and structure of peptides as a resource for development of new
560   therapeutics. Nucleic Acids Res *49*, D288–D297.
561   https://doi.org/10.1093/nar/gkaa991.

562   36.   Eisenberg, D., Schwarz, E., Komaromy, M., and Wall, R. (1984). Analysis of
563   membrane and surface protein sequences with the hydrophobic moment plot. J
564   Mol Biol *179*, 125–142. https://doi.org/https://doi.org/10.1016/0022-
565   2836(84)90309-7.

566   37.   Rice, P., Longden, I., and Bleasby, A. (2000). EMBOSS: The European
567   Molecular Biology Open Software Suite. Trends in Genetics *16*, 276–277.
568   https://doi.org/10.1016/S0168-9525(00)02024-2.

569   38.   Cock, P.J.A., Antao, T., Chang, J.T., Chapman, B.A., Cox, C.J., Dalke, A.,
570   Friedberg, I., Hamelryck, T., Kauff, F., Wilczynski, B., et al. (2009). Biopython:
571   freely available Python tools for computational molecular biology and
572   bioinformatics. Bioinformatics *25*, 1422–1423.
573   https://doi.org/10.1093/bioinformatics/btp163.

574

575   **Methods**

576   **Encrypted peptides in venom proteomes**

577   The venom protein sequences were collected from https://www.snakebd.com/ (Snakes),

578   https://arachnoserver.qfab.org/mainMenu.html (Spider), https://www.conoserver.org/

579   (Carnivorous marine cone snails) and https://venomzone.expasy.org/ (Venom Zone)

580   (access data: August 30th, 2023). 654, 2,206, 5,494 and 7,769 proteins were obtained

20

581 from above four databases, respectively. Venom protein substrings ranging from 8-50

582 amino acids in the sequences, comprising only canonical amino acids, were considered

583 as the venom encrypted peptides (VEPs). The venom proteins were preprocessed in

584 three ways based on length: (1) no truncation for lengths ≥8; (2) truncation using a

585 sliding window (range from 8 to maximum sequence length) for lengths between 8 and

586 50; (3) truncation using a sliding window (range from 8 to 50) for lengths >50. In total,

587 40,626,260 VEPs were obtained from venom proteins sequences, which were for further

588 study.

589 **APEX**

590 APEX is a bacterial strain-specific antimicrobial activity predictor[9], and was trained on

591 in-house peptide dataset and publicly available antimicrobial peptides (AMPs) from

592 DBAASP[34]. Specifically, APEX is a multiple-target tasks model that can predict

593 minimum inhibitory concentrations (MICs) values of peptides against 34 bacterial

594 strains (*E. coli* ATCC 11775, *P. aeruginosa* PAO1, *P. aeruginosa* PA14, *S. aureus*

595 ATCC 12600, *E. coli* AIC221, *E. coli* AIC222, *K. pneumoniae* ATCC 13883, *A.*

596 *baumannii* ATCC 19606, *Akkermansia muciniphila* ATCC BAA-835, *Bacteroides*

597 *fragilis* ATCC 25285, *Bacteroides vulgatus (Phocaeicola vulgatus)* ATCC 8482,

598 *Collinsella aerofaciens* ATCC 25986, *Clostridium scindens* ATCC 35704, *Bacteroides*

599 *thetaiotaomicron* ATCC 29148, *B. thetaiotaomicron* Δ*tdk* Δ*lpxF* (background: VPI

600 5482), *Bacteroides uniformis* ATCC 8492, *Bacteroides eggerthi* ATCC 27754,

601 *Clostridium spiroforme* ATCC 29900, *Parabacteroides distasonis* ATCC 8503,

602 *Prevotella copri* DSMZ 18205, *Bacteroides ovatus* ATCC 8483, *Eubacterium*

603 *rectale ATCC 33656, Clostridium symbiosum ATCC 14940, Ruminococcus*

604 *obeum ATCC 29174, Ruminococcus torques ATCC 27756, methicillin-resistant S.*

605 *aureus ATCC BAA-1556, vancomycin-resistant Enterococcus faecalis ATCC 700802,*

606 *vancomycin-resistant E. faecium ATCC 700221, E. coli Nissle 1917, Salmonella*

607 *enterica ATCC 9150 (BEIRES NR-515), S. enterica (BEIRES NR-170), S.*

608 *enterica ATCC 9150 (BEIRES NR-174) and Listeria monocytogenes ATCC 19111*

609 *(BEIRES NR-106)*

610 **Venom encrypted peptide selection**

611 APEX was used to predict the antimicrobial activity for the 40,626,260 encrypted

612 peptides derived from the venom proteome. We used the mean MIC value against the

613 eleven pathogen strains to rank and select the encrypted peptides for chemical synthesis

21

614 and experimental validation. When selecting the peptides, we also make sure they met

615 the following criteria:

616 1 – The selected peptide should have ≤32 µmol L^{-1} median MIC by prediction.

617 2 – The selected peptide should have <75% sequence similarity to all in-house peptides

618 and publicly available AMPs.

619 3 – The selected peptides themselves should have <75% sequence similarity.

Physicochemical property analysis

621 The twelve physicochemical properties of peptides, including normalized hydrophobic

622 moment, normalized hydrophobicity, net charge, isoelectric point, penetration depth, tilt

623 angle, disordered conformation propensity, linear moment, propensity to aggregation *in*

624 *vitro*, angle subtended by the hydrophobic residues, amphiphilicity index, and

625 propensity to PPII coil, were obtained from the DBAASP server[35]. Note that Eisenberg

626 and Weiss scale[36] was chosen as the hydrophobicity scale.

Phylogenetic tree visualization

628 To obtain the phylogenetic tree, the taxon IDs of organisms obtained from four

629 databases   were   uploaded   to   NCBI   Taxonomy   Common   Tree

630 (https://www.ncbi.nlm.nih.gov/Taxonomy/CommonTree/wwwcmt.cgi).   The   resulted

631 tree file from NCBI was then visualized via iTOL (https://itol.embl.de/).

Peptide sequence similarity

633 We applied the Needleman–Wunsch algorithm in the function 'needleall' from the

634 EMBOSS software package (version 6.6.0.0)[37] to estimate the similarity between our

635 VEP   with   median   MIC   ≤32   µmol   L^{-1} and   AMPs   in   the   DBAASP dataset. The

636 parameters used are all default, and the parameter 'identity' was sifted out for the graph.

AA frequencies calculation

638 The function 'ProtParam.ProteinAnalysis' was imported from the Biopython module

639 'Bio.SeqUtils.ProtParam' (version 1.75)[38], which was used to count the total number of

640 amino acids in a protein sequence and calculate the percentage composition of each

641 amino acid in a protein sequence for two levels analysis including amino acid level and

642 sequence level.

643 Amino acid level:

$$AA_i = \frac{\sum_{j=1}^{n} aa_{ij}}{\sum_{i}^{20} \sum_{j=1}^{n} aa_{ij}}$$

644 Where aa_{ij} is the number of amino acid i in sequence j and AA_i is the frequency of

645 amino acid I. n is the total number of sequences and 20 is the total number of amino

646 acids.

647 Sequence level:

$$AA_i = \frac{\sum_{j=1}^{n} aa_{ij}}{n}$$

648 Where aa_{ij} is the frequency of amino acid i in sequence j and AA_i is the frequency of

649 amino acid i. n is the total number of sequences.

650 **Peptide sequence space visualization**

651 Given a peptide dataset, a similarity matrix containing the pairwise peptide sequence

652 similarity could be calculated by previous method (Peptide sequence similarity).

653 Uniform manifold approximation and projection (UMAP) was then used to transform

654 the similarity matrix into a two-dimensional space. We used this space as a proxy for

655 the peptide sequence space, and visualized the peptides' distribution/spread/location in

656 it.

657 **Peptide Synthesis**

658 All peptides used in the experiments were purchased from AAPPTec and synthesized

659 by solid-phase peptide synthesis using the Fmoc strategy.

660 **Bacterial strains and growth conditions**

661 In this study, we used the following pathogenic bacterial strains: *Acinetobacter*

662 *baumannii* ATCC 19606, *Escherichia coli* AIC221 [*Escherichia coli* MG1655

663 phnE_2::FRT (control strain for AIC 222)] and *Escherichia coli* AIC222 [*Escherichia*

664 *coli* MG1655 pmrA53 phnE_2::FRT (polymyxin resistant; colistin-resistant strain)],

665 *Klebsiella pneumoniae* ATCC 13883, *Pseudomonas aeruginosa* PAO1, *Pseudomonas*

666 *aeruginosa* PA14, *Staphylococcus aureus* ATCC 12600, methicillin-resistant

667 *Staphylococcus aureus* ATCC BAA-1556, vancomycin-resistant *Enterococcus faecalis*

668 ATCC 700802, and vancomycin-resistant *Enterococcus faecium* ATCC 700221.

669 Pseudomonas Isolation (*Pseudomonas aeruginosa* strains) agar plates were exclusively

670 used in the case of *Pseudomonas* species. All the other pathogens were grown in Luria-

671 Bertani (LB) broth and on LB agar. In all the experiments, bacteria were inoculated

23

672   from one-isolated colony and grown overnight (16 h) in liquid medium at 37 °C. In the

673   following day, inoculums were diluted 1:100 in fresh media and incubated at 37 °C to

674   mid-logarithmic phase.

Minimal inhibitory concentration assays

676   Broth microdilution assays were performed to determine the minimum inhibitory

677   concentration (MIC) values of each peptide. Peptides were added to nontreated

678   polystyrene microtiter 96-well plates and 2-fold serially diluted in sterile water from 1

679   to 64 µmol L^{-1}. Bacterial inoculum at 2×10^6 CFU mL^{-1} in LB or BHI medium was

680   mixed 1:1 with the peptide. The MIC was defined as the lowest concentration of peptide

681   able to completely inhibit the bacterial growth after 24 h of incubation at 37 °C. All

682   assays were done in three independent replicates.

Circular dichroism experiments

684   The circular dichroism experiments were conducted using a J1500 circular dichroism

685   spectropolarimeter (Jasco) in the Biological Chemistry Resource Center (BCRC) at the

686   University of Pennsylvania. Experiments were performed at 25 °C, the spectra graphed

687   are an average of three accumulations obtained with a quartz cuvette with an optical

688   path length of 1.0 mm, ranging from 260 to 190 nm at a rate of 50 nm min^{-1} and a

689   bandwidth of 0.5 nm. The concentration of all VEPs tested was 50 µmol L^{-1}, and the

690   measurements were performed in water, mixture of water and trifluoroethanol (TFE) in

691   a 3:2 ratio, mixture of water and methanol (MeOH) in a 1:1 ratio, and sodium dodecyl

692   sulfate (SDS) in water at 10 mmol L^{-1}, with respective baselines recorded prior to

693   measurement. A Fourier transform filter was applied to minimize background effects.

694   Helical fraction values were calculated using the single spectra analysis tool on the

695   server BeStSel[26]. Ternary plots were created in https://www.ternaryplot.com/ and

696   subsequently edited.

Outer membrane permeabilization assays

698   N-phenyl-1-napthylamine (NPN) uptake assay was used to evaluate the ability of the

699   peptides to permeabilize the bacterial outer membrane. Inocula of *P. aeruginosa* PAO1

700   were grown to an OD at 600 nm of 0.4 mL^{-1}, centrifuged (10,000 rpm at 4 °C for 10

701   min), washed and resuspended in 5 mmol L^{-1} HEPES buffer (pH 7.4) containing 5

702   mmol L^{-1} glucose. The bacterial solution was added to a white 96-well plate (100 µL

703   per well) together with 4 µL of NPN at 0.5 mmol L^{-1}. Consequently, peptides diluted in

704   water were added at their MIC to each well, and the fluorescence was measured at $\lambda_{ex} =$

705   350 nm and λ_{em} = 420 nm over time for 45 min. The relative fluorescence was

706   calculated using the untreated control (buffer + bacteria + fluorescent dye) and

707   polymyxin B (positive control) as baselines and the following equation was applied to

708   reflect % of difference between the baselines and the sample:

$$\% \, difference = \frac{100 * (fluorescence_{sample} - fluorescence_{untreated \, control})}{fluorescence_{untreated \, control}}$$

709   **Cytoplasmic membrane depolarization assays**

710   The cytoplasmic membrane depolarization assay was performed using the membrane

711   potential-sensitive dye 3,3'-dipropylthiadicarbocyanine iodide (DiSC$_3$-5). *P. aeruginosa*

712   PAO1 and *S. aureus* ATCC 12600 in the mid-logarithmic phase were washed and

713   resuspended at 0.05 OD mL^{-1} (optical value at 600 nm) in HEPES buffer (pH 7.2)

714   containing 20 mmol L^{-1} glucose and 0.1 mol L^{-1} KCl. DiSC$_3$-5 at 20 µmol L^{-1} was added

715   to the bacterial suspension (100 µL per well) for 15 min to stabilize the fluorescence

716   which indicates the incorporation of the dye into the bacterial membrane, and then the

717   peptides were mixed 1:1 with the bacteria to a final concentration corresponding to their

718   MIC values. Membrane depolarization was then followed by reading changes in the

719   fluorescence (λ_{ex} = 622 nm, λ_{em} = 670 nm) over time for 60 min. The relative

720   fluorescence was calculated using the untreated control (buffer + bacteria + fluorescent

721   dye) and polymyxin B (positive control) as baselines and the following equation was

722   applied to reflect % of difference between the baselines and the sample:

$$\% \, difference = \frac{100 * (fluorescence_{sample} - fluorescence_{untreated \, control})}{fluorescence_{untreated \, control}}$$

723   **Eukaryotic cells culture**

724   HEK293T cells were obtained from the American Type Culture Collection (CRL-3216).

725   The cells were cultured in high-glucose Dulbecco's modified Eagle's medium

726   supplemented with 1% penicillin and streptomycin (antibiotics) and 10% fetal bovine

727   serum and grown at 37 °C in a humidified atmosphere containing 5% CO_2.

728   **Cytotoxicity assays**

729   One day before the experiment, an aliquot of 100 µL of the cells at 50,000 cells per

730   mL was seeded into each well of the cell-treated 96-well plates used in the experiment

731 (that is, 5,000 cells per well). The attached HEK293T cells were then exposed to

732 increasing concentrations of the peptides (8–128 µmol L^{-1}) for 24 h. After the

733 incubation period, we performed the 3-(4,5-dimethylthiazol-2-yl)-2,5-

734 diphenyltetrazolium bromide tetrazolium reduction assay (MTT assay). The MTT

735 reagent was dissolved at 0.5 mg mL^{-1} in medium without phenol red and was used to

736 replace cell culture supernatants containing the peptides (100 µL per well), and the

737 samples were incubated for 4 h at 37 °C in a humidified atmosphere containing 5%

738 CO_2 yielding the insoluble formazan salt. The resulting salts were then resuspended in

739 hydrochloric acid (0.04 mol L^{-1}) in anhydrous isopropanol and quantified by

740 spectrophotometric measurements of absorbance at 570 nm. All assays were done as

741 three biological replicates.

742 **Skin abscess infection mouse model**

743 The back of six-week-old female CD-1 mice under anesthesia were shaved and injured

744 with a superficial linear skin abrasion made with a needle. An aliquot of *A. baumannii*

745 ATCC 19606 (9.6×10^5 CFU mL^{-1}; 20 µL) previously grown in LB medium until OD

746 (optical value at 600 nm) 0.5 and then washed twice with sterile PBS (pH 7.4, 10,000

747 rpm for 2 min) was added to the scratched area. Peptides diluted in sterile water at MIC

748 value were administered to the wound area 2 h after the infection. Two- and four-days

749 post-infection animals were euthanized, and the scarified skin was excised,

750 homogenized using a bead beater (25 Hz for 20 min), 10-fold serially diluted, and

751 plated on McConkey agar plates for CFU quantification. The experiments were

752 performed using six mice per group (n = 6). The skin abscess infection mouse model

753 was revised and approved by the University Laboratory Animal Resources (ULAR)

754 from the University of Pennsylvania (Protocol 806763).

755

756 **Quantification and statistical analysis**

757 *Reproducibility of the experimental assays*

758 Unless otherwise stated, all assays were performed in three independent biological

759 replicates as indicated in each figure legend and Experimental Models and Methods

760 details sections. The values obtained for cytotoxic activity were estimated by non-linear

761 regression based on the screen of peptides in a gradient of concentrations and represent

762 the cytotoxic concentration values needed to lyse and kill 50% of the cells present in the

763   experiment. In the skin abscess mouse model, we used six mice per group following

764   established protocols approved by the University Laboratory of Animal Resources

765   (ULAR) of the University of Pennsylvania.

766   ***Statistical tests***

767   In the mouse experiments, all the raw data underwent $\log_{10}$ transformation and the

768   statistical significance was determined using one-way ANOVA followed by Dunnett's

769   test. All the P-values are shown for each of the groups, all groups were compared to the

770   untreated control group.

771   ***Statistical analysis***

772   All calculation and statistical analyses of the experimental data were conducted using

773   GraphPad Prism v.10.0.2. Statistical significance between different groups was

774   calculated using the tests indicated in each figure legend. No statistical methods were

775   used   to   predetermine   sample   size.

776 **Supplementary Information**

777 **Supplementary Table 1.** Database-sourced venom protein and VEP candidates.

Database	Number of proteins mined	Number of candidate antibiotics (MIC ≤32 µmol L^{-1})	Number of candidates removed by similarity to known AMPs	Candidates (diversity filter)
ConoServer	5494	377	377	26
ArachnoServer	2206	2205	2154	80
ISOB	654	179	40	7
VenomZone (UniProtPK)	7769	4618	3731	273

778 **Supplementary Table 2.** Antibiotics selected for synthesis and experimental validation.

| Peptide	Sequence	Peptide	Sequence
UniprotKB-1	KLLKIGLKSFARVLKKVL	Conoserver-3	RRASPLWKRRRFLSMLKARAKRTGYK
UniprotKB-2	WLGSALKIGAKLL	Conoserver-4	PLWKRRRFLSMLKARAKR
UniprotKB-3	KLWNSKLARKIRTKGLKYVKNFAK	Conoserver-5	LRAKMLNSKFIKL
UniprotKB-4	LKLKSILGKLGVIL	Conoserver-6	KLHGLLTRRSLKNFWKRNLYLR
UniprotKB-5	RRVKRFKKFFMKLKKSVKKRVMKFFK	Conoserver-7	KRGRASPLWQRRGFLSKLKARAKRNGAFHLPR
UniprotKB-6	GKWLISSLVAKHL	Conoserver-10	RLRAKMRNSKLFKLTKR
UniprotKB-7	KRLKGFAKKLWNSKLARKIRTKGLKYVKNFAK	Conoserver-12	RQEYPTKRLRAKMLNSKFIKLIKR
UniprotKB-8	KLKKLRKWIYRIV	Conoserver-14	KKWRELSRLSRVLQIL
UniprotKB-9	FLKKIWRSKLVKRL	Conoserver-15	RKRRRFISMLKARAKRR
UniprotKB-10	KRRRASPLWKRRRFLSMLKARAK	Conoserver-16	KQKYLIKRSRAKMQNHKLFKLTKR
UniprotKB-11	LTKWLGKLGVIL	Arachnoserver-1	KLLKIGLKSFARVLKKVL
UniprotKB-12	RKFKWGKLFSTAKKLYKKGKKLSKNKNFKKALK	Arachnoserver-2	RKFKWGSFKKILSAGKKLFKKAKKLSK
UniprotKB-13	KFLARLVFRKFILL	Arachnoserver-4	KWGKLFSAGKKLLKKAKKL
UniprotKB-14	KNKRFIRNLRSNLYQKIIKSTKSLL	Arachnoserver-5	KIKWLKAMKSIAKFIAKK
UniprotKB-15	KWLGKLGVILSHL	Arachnoserver-6	RKFKWGSFKKILSAGKKLFKKAKKLSKNKNFKKALK
UniprotKB-16	RKFKWGKLFSTAKKLYKKGKKLSK	Arachnoserver-7	RKFNWGKLFKSAKKLYKTGKKLSKNKNVRKALKFGK

29

UniprotKB-17	FIKKLWRSKLAKKLRAKGRELLK	Arachnoserver-9	KNKRFIRNLRSNLYQKIIKSTKSLL
UniprotKB-18	RRVKRFKKFFMKL	Arachnoserver-11	ARKFKWGKLFSAGKKLLKKAKKLSKNK
UniprotKB-19	VNSFKIGGFIKKLWRSKLAKKLRAK	Arachnoserver-12	RGLAKLLKIGLKSFARVLKK
UniprotKB-20	RFGSFLKKVWKSKLAKKL	Arachnoserver-17	KRFIRNLRSNLYQKIIKSTKSLLDLREKI
ISOB-1	RRVKRFKKFFRKLKKSVKKRAKEFFK	Arachnoserver-18	KFSVFSKILRSIAKVF
ISOB-2	RHRIVRTYIAKFGLK	Arachnoserver-19	SKKQIRLYLLKYYGKKLFKKRPK
ISOB-3	KRKGYLRLVPEERIWQKGLWWLRRLETDSDKLQK	Arachnoserver-20	KKQIRLYLLKYYGKKSSSKSVRKIVISK
ISOB-4	LLHFSIWRSTVLRK	Arachnoserver-27	KFSVFSKILRSIAKVFKGVGKVRK
ISOB-5	RHRIVRTYIAKFGLKLNEFFQENENAWYFIRNIRKRVWEVKK	Arachnoserver-28	KLSGISKVLRAIAKFFK
ISOB-6	RRVKRFKKFFKKL	Arachnoserver-29	SFKKILSAGKKLFKKAKKL
ISOB-7	QPRRVKRFKKFFKKLKNSVKKRAKKF	Arachnoserver-31	KYRRGVSPWLKKELVRLHNNLRSKVAGGK
Conoserver-1	KRLRAKMLNSKFIKLIKR	Arachnoserver-32	KWLKAMKSIAKFIAKKQMKKHL
Conoserver-2	KRRRASPLWKRRRFLSMLKARAK	Arachnoserver-33	KIKWFKTMKSLAKFLAK

Supplementary Figure 1. Phylogenetic analysis of venom protein, peptide, predicted AMP, and verified AMP across species in ConoServer. This phylogenetic tree illustrates the distribution of venom proteins, peptides, predicted antimicrobial peptides (AMPs), and experimentally verified AMPs among species in ConoServer. The tree was constructed using taxon IDs of organisms. From the inside to the outside, circle 1: Venom protein count per organism; Circle 2: Peptide count derived from venom proteins per organism; Circle 3: Predicted AMP count from venom proteins per organism; Circle 4: Experimentally verified AMP count per organism.

793

Supplementary Figure 2. Distribution analysis of venom protein, peptide, predicted AMP, and verified AMP across species in ArachnoServer. This phylogenetic tree illustrates relationship distance of different organisms. The tree was constructed using taxon IDs of organisms. From the inside to the outside, circle 1: Venom protein number; Circle 2: Peptide number; Circle 3: Predicted AMP number; Circle 4: Experimentally verified AMP number.

800

801

802

803

804

805

Supplementary Figure 3. The distribution of venom protein, peptide, predicted AMP, and verified AMP across species in ISOB. This phylogenetic tree illustrates the phylogenetic relationship of species in ConoServer, which contained the number of venom proteins, peptides, predicted antimicrobial peptides (AMPs), and experimentally verified AMPs among. The four circles represent, from the inside to the outside, number of venom protein, number of peptides, number of predicted AMP, number of experimentally validation AMP.

819

Supplementary Figure 4. Phylogenetic analysis of species in UniProt and distribution analysis of the number of venom protein, peptide, predicted AMP, and verified AMP across species in UniProt. This evolutionary tree shows the evolutionary relationships between species in ConoServer. The four circles represent, from the inside to the outside, the number of venom proteins contained in each organism, the number of peptides produced by the venom proteins of each organism, the number of predicted AMPs contained in each organism, and the number of experimentally verified AMPs contained in each organism.

828

829

830

831

832

833

834

835

Supplementary Figure 5. Physicochemical properties space exploration using a similarity matrix. The graph illustrates a bidimensional physicochemical properties space visualization of peptide sequences found in DBAASP and antimicrobial venom-derived EPs (VEPs) discovered by APEX in venom proteins from multiple source organisms. Sequence alignment was used to generate a similarity matrix for all peptide sequences in DBAASP and the predicted antimicrobial VEPs (see also **Data S1**). Each row in the matrix represents a feature representation of a peptide based on its amino acid composition. Uniform Manifold Approximation and Projection (UMAP) was applied to reduce the feature representation to two dimensions for visualization.

845

**Supplementary Figure 6. VEPs amino acid frequency at amino acid residues level.** Comparison between VEPs and known antimicrobial peptides (AMPs) from the DBAASP, APD3, and DRAMP 3.0 databases at amino acid level.

846

847

848

849

850

851

852

853
854 **Supplementary Figure 7. Physicochemical features of VEPs compared to AMPs**

855 **from databases (DBAASP, APD3, and DRAMP 3.0). (a)** Amphiphilicity Index, **(b)**

856 Isoelectric Point, and **(c)** Hydrophobic moment normalized by peptide length, reflecting

857 the amphipathicity of the molecules, which directly influences their interactions with

858 bacterial membranes. **(d)** Propensity to aggregate *in vitro*, correlated with the

37

859   supramolecular arrangement of the molecules and potential toxicity. Statistical

860   significance was determined using two-tailed t-tests followed by the Mann-Whitney

861   test; p values are shown in the graph. The solid line within each box represents the mean

862   value for each group.

863

864

865

866

867

868

Supplementary Figure 8. Circular dichroism spectra of VEPs. Circular dichroism experiments were conducted with peptides from venoms using a J-1500 Jasco circular dichroism spectrophotometer. The spectra were recorded in four different media: **(a)** water, **(b)** 60% trifluoroethanol in water, and **(c)** sodium dodecyl sulfate (SDS) in water (10 mmol L^{-1}), and **(d)** 50% methanol in water, after three accumulations at 25 $^{\circ}$C, using a 1mm path length quartz cell, between 260 and 190 nm at 50 nm min^{-1}, with a bandwidth of 0.5 nm. The concentration of all peptides tested was 50 μmol L^{-1}. **(d)** Heatmap with the percentage of secondary structure found for each peptide in the four different solvents. Secondary structure fraction was calculated using the BeStSel server[15].

881

Supplementary Figure 9. Outer membrane permeabilization and cytoplasmic membrane depolarization of *P.aeruginosa* PAO1 and *S. aureus* ATCC 12600 induced by VEPs. (a) Outer membrane permeabilization was assessed using the probe 1-(N-phenylamino)naphthalene (NPN), showing the permeabilization effects of VEPs active against *P. aeruginosa* PAO1. **(b)** Membrane depolarization assays were

887 performed using the hydrophobic probe 3,3'-dipropylthiadicarbocyanine iodide (DiSC$_3$-

888 5) on all VEPs active against *P. aeruginosa* PAO1 and *S. aureus* ATCC 12600.

889 Polymyxin B and levofloxacin served as antibiotic controls, while buffer, buffer with

890 the probe, and buffer with both probe and bacteria were used as baseline controls for

891 fluorescence. The panels display the raw fluorescence intensity data obtained from the

892 experiments. Error bars are the standard deviation obtained from the three replicates.

893

894

895

896

897

898

899

900

901

902

903

Supplementary Figure 10. Weight change monitoring in skin abscess mouse model infected with *A. baumannii*. Mouse weight was monitored throughout the duration of the skin abscess model (4 days total) to assess potential toxic effects of both the bacterial load and the VEPs.